Home » Medical Devices » Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market By Clinical Causes (Inflammatory Disease, Neurotrophic Keratitis (NK), Epithelial/Limbal Stem Cell Deficiency, Others) By Type (Device, Medication) By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) By End User (Hospitals, Home-care, Specialty Clinics, Others)- Growth, Share, Opportunities & Competitive Analysis, 2016 – 2028

Price: $4999

Published: | Report ID: 14389 | Report Format : PDF

How do the Neoantigen-Based Personalized Cancer Therapeutic Vaccines work?

Cancer vaccines induce an immune response in the body by using weakened or killed viruses, bacteria, or other infection-causing agents. Cancer is the leading cause of death in the world, accounting for nearly 10 million deaths in 2020, or almost one in every six.

Breast, lung, colon, rectum, and prostate cancers are the most common. Companies, universities, and associations are collaborating to assess challenges and identify opportunities in the research and development of Neoantigen-based Personalized Cancer Therapeutic Vaccines. These vaccines work similarly, with the immune system recognizing, attacking, and destroying cancer cells.

Neoantigens derived from cancer-specific mutations are another appealing class of antigens for therapeutic cancer vaccines. Vaccination against tumor-specific neoantigens reduces the risk of induction of central and peripheral tolerance and autoimmunity. Neoantigen-based cancer vaccines have recently demonstrated significant therapeutic potential in preclinical and early-phase clinical trials.

Tumor-specific antigens, also known as neoantigens, are not found in normal cells and are derived from random somatic mutations in tumor cells.

These Neoantigen-based Personalized Cancer Therapeutic Vaccines, which are being developed based on novel technology platforms approaches, will help advance precision medicine by providing feasible tools for analyzing the mutation antigen profile, gene signature, and epigenetic modification of tumor and immune cells, as well as the magnitude, homing capacity, cytotoxic function, and T cell receptor (TCR) repertoire of T lymphocytes.

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market

What is the Market Size of Neoantigen-Based Personalized Cancer Therapeutic Vaccines in terms of value?

The global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market is projected to increase at a significant CAGR of XX% in the coming years. In 2021, the global Neoantigen-Based Personalized Cancer Therapeutic Vaccines market was valued at USD XX billion and projected to reach USD XX billion by 2028.

The demand for Neoantigen-Based Personalized Cancer Therapeutic Vaccines is projected to increase substantially in the coming years and is presumed to generate revenue opportunities for the key industry players worth USD XX billion during the forecast period of 2022 and 2028.

What are the key emerging vaccines for Neoantigen-Based Personalized Cancer Therapeutic Vaccines?

GEN-009 Adjuvanted Vaccine: Genocea Biosciences-

GEN-009 is a personalized cancer vaccine that optimizes target selection using Genocea’s proprietary ATLAS platform, giving the vaccine the best chance of targeting the right tumor mutations in each person.

Tedopi (OSE2101): OSE Immunotherapeutics

Tedopi, neoantigen-based immunotherapy in development for the treatment of HLA-A2+ NSCLC, is SE Immunotherapeutics’ lead clinical immune-oncology asset. It combines ten optimized neo-epitopes and protein fragments that structurally alter cancer cells and activate strong immune responses against them.

TG01 Vaccine: Targovax

Targovax is developing TG01, a Neoantigen-specific peptide vaccine that targets AS mutations that cause uncontrolled cell divisions in solid tumors. It has created a one-of-a-kind vaccine against mutant RAS.

NEO-PV-01: Neon Therapeutics

NEO-PV-01 is a fully personalized cancer vaccine that targets neoantigens that are individually designed and manufactured for each patient based on the tumor’s unique mutational fingerprint.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Interesting Facts about Neoantigen-Based Personalized Cancer Therapeutic Vaccines Industry

  • The Neoantigen-Based Personalized Cancer Therapeutic Vaccines market has been primarily attributed to significant market drivers such as rising cancer prevalence, increasing adoption of personalized medicine to tailor patient treatment on an individual level, and significant external funding for research and development exercises.
  • North America region had a considerable share in volume and value in the global Neoantigen-Based Personalized Cancer Therapeutic Vaccines market in 2021 and is projected to continue its dominance over the forecast period.
  • According to vaccine Route of Administrations, neo-antigen based mRNA vaccines, neo-antigen based Viral/Bacterial vaccines, neo-antigen based polypeptide vaccines, neo-antigen based Dendritic cell vaccines, immunotherapy-based vaccines, and allogeneic and autologous tumor cell based neo-antigen vaccines will be available.
  • Companies, universities, and associations collaborate to assess challenges and identify opportunities for Neoantigen-based Personalized Cancer Therapeutic Vaccines R&D.

Who are the Top 10 players/companies in the Neoantigen-Based Personalized Cancer Therapeutic Vaccines market regarding value?

The key players in the global Neoantigen-Based Personalized Cancer Therapeutic Vaccines market in terms of value include NEC Corporation, BrightPath therapeutics, CUREVAC N.V., Geneos Therapeutics, Vaccibody, Transgene, Neon Therapeutic, Genocea Biosciences, Moderna, Advaxis, AstraZeneca, Gritstone Oncology, Inc., Incyte Corporation, Hangzhou Neoantigen Therapeutics, and Frame Pharmaceuticals.

These key players are concentrating on new product developments as well as technological innovation to enhance their production of Neoantigen-Based Personalized Cancer Therapeutic Vaccines to gain competitive market share at a global level. For instance, OSE Immunotherapeutics, which is developing the Tedopi (OSE2101) neoantigen cancer vaccine, is set to launch in 2022.

Tedopi (OSE2101) is a drug used to treat patients with HLA-A2+ non-small cell lung cancer (NSCLC). The vaccine is currently in phase III of clinical development.

On the other hand, BioNTech SE is a German company that manufactures neoantigen vaccines. Individualized Vaccines Against Cancer (IVAC) Mutanome platform developed by BioNTech SE engineers RNA molecules to produce customized neoantigen vaccine.

IVAC clinical trials for triple-negative breast cancer, multiple tumor Route of Administrations, and melanoma are currently underway.

Who are the Top 10 Countries in the Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market?

The major countries in the global Neoantigen-Based Personalized Cancer Therapeutic Vaccines market are the US, Canada, China, Japan, Australia, Germany, France, Italy, Spain, and the UK. The largest market share is in the United States.

In the United States, in 2019, 1,752,735 new cancer cases were reported, and 599,589 cancer deaths were reported. Four hundred thirty-nine new cancer cases were reported for every 100,000, and 146 died from cancer. However, increased funding for research and development activities in the United States is helping propel the global neoantigen cancer vaccine market forward.

Neon Therapeutics, a US-based company, launched NEO-PV-01, which is a fully personalized cancer vaccine that targets neoantigens that are custom-designed and manufactured for each patient based on the tumor’s unique mutational fingerprint. NEO-neoantigen-targeting PV-01 peptides elicit an antitumor immune response that directs patients’ T-cells to target and kill cancer cells.

Multiple phases I clinical trials for Urinary Bladder Cancer, Non-small Cell Lung Cancer, and Metastatic Melanoma are currently underway. Similarly, Agenus Inc. created the AutoSynVax (ASV) neoantigen vaccine, which is used in conjunction with the adjuvant QS-21 Stimulon to treat solid tumors. ASV is currently in Phase 1 clinical trials in the United States.

Which is the Key molecule Route of Administration segment in the Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market?

Gene therapy is expected to grow at a substantial rate in the neoantigen-based personalized cancer therapeutic vaccine market over the forecast period. Gene therapy is a medical field that focuses on genetically altering cells to provide a therapeutic effect or to heal disease by repairing or reconstructing damaged genetic material.

The goal of gene therapy is to address a congenital illness at its root. If, for instance, a mutation in a specific gene results in the production of a dysfunctional protein, resulting (usually recessively) in inherited disease, gene therapy could be used to deliver a copy of this gene that does not contain the deleterious mutation, resulting in the production of a functional protein. This method is known as gene replacement therapy and is used to treat inherited retinal disorders.

What are the Major Driving Factors for the Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market?

The Neoantigen-Based Personalized Cancer Therapeutic Vaccines have expanded primarily due to significant market drivers such as rising cancer prevalence, increased adoption of personalized medicine to tailor patient treatment on an individual level, and significant external funding for research and development.

Rapid technological advancements and infrastructure developments in the healthcare sector, on the other hand, are propelling the Neoantigen-Based Personalized Cancer Therapeutic Vaccines market forward. Furthermore, rising investments by governments and healthcare providers are expected to drive the global neoantigen cancer vaccine market in the coming years.

In addition, growing awareness of the unmet need for adjuvant therapies and incremental healthcare spending around the world is also expected to increase market size and allow vaccine manufacturers to penetrate further into the market.

What are the Major Restraints for the Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market?

Higher cost of personalized cancer vaccines, challenges in clinical development and optimization process, and uncertain reimbursement scenarios are the major restraint factors in Neoantigen-Based Personalized Cancer Therapeutic Vaccines market growth. In addition, payer uncertainty, outcome-based pricing, and high capital requirements are also impeding global Neoantigen-Based Personalized Cancer Therapeutic Vaccines market expansion.

Which Region Dominated the World Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market?

In 2021, North America will dominate the Neoantigen-Based Personalized Cancer Therapeutic Vaccines market over the forecast period due to the prevalence of advanced healthcare infrastructure and rising cancer incidences.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

A total of 1.9 million cancer cases were reported in North America. Breast (14 percent), lung (13 percent), prostate (12 percent), colorectum (10 percent), bladder (5 percent), non-Hodgkin lymphoma (4 percent), melanoma of the skin (4 percent), and other cancers are the most common (38 percent ). An estimated 693,000 people died from cancer.

Rapid technological advancements and healthcare infrastructure developments, on the other hand, are propelling the Neoantigen-Based Personalized Cancer Therapeutic Vaccines market forward. Additionally, rising government and healthcare provider investments are expected to propel the global neoantigen cancer vaccine market in the coming years. Rising awareness of the unmet need for adjuvant therapies and increased healthcare spending globally is expected to increase market size and allow vaccine manufacturers to expand their market penetration.

The Asia Pacific is expected to have the highest growth rate and growth rate during the forecast period. This is due to rising healthcare infrastructure development costs and the growth and increased awareness of personalized cancer vaccines.

Growing government and healthcare provider investments are expected to drive the global neoantigen cancer vaccine market in the coming years. In addition, rising awareness of the unmet need for adjuvant therapies and increased healthcare spending globally are expected to increase market size and allow vaccine manufacturers to expand their market penetration.

Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market – By Drugs by the Route of Administration

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market – By Molecule Route of Administration

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

1. Preface

1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Segmentation

2. Executive Summary
2.1. Market Snapshot: Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market Value, 2016-2028, (US$ Bn)
3.2. Market Dynamics
3.2.1. Key Growth Trends
3.2.2. Major Industry Challenges
3.2.3. Key Growth Pockets
3.3. Attractive Investment Proposition,2021
3.3.1. Route of Administration
3.3.2. Molecule Type
3.3.3. Geography
3.4. Porter’s Five Forces Analysis
3.4.1. Threat of New Entrants
3.4.2. Bargaining Power of Buyers/Consumers
3.4.3. Bargaining Power of Suppliers
3.4.4. Threat of Substitute Route of Administrations
3.4.5. Intensity of Competitive Rivalry
3.5. Value Chain Analysis

4. Market Positioning of Key Players, 2021
4.1. Company market share of key players, 2021
4.2. Top 6 Players
4.3. Top 3 Players
4.4. Major Strategies Adopted by Key Players

5. COVID 19 Impact Analysis
5.1. Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market Pre Vs Post COVID 19, 2019 – 2028
5.2. Impact on Import & Export
5.3. Impact on Demand & Supply

6. North America
6.1. North America Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Country, 2016-2028(US$ Bn)
6.1.1. U.S.
6.1.2. Canada
6.1.3. Mexico
6.2. North America Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Route of Administration, 2016-2028(US$ Bn)
6.2.1. Overview
6.2.2. Oral
6.2.3. Parenteral
6.2.4. Intravenous
6.2.5. Subcutaneous
6.2.6. Topicals
6.2.7. Others
6.3. North America Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Molecule Type, 2016-2028(US$ Bn)
6.3.1. Overview
6.3.2. Monoclonal Antibody
6.3.3. Peptides
6.3.4. Polymer
6.3.5. Small molecule
6.3.6. Gene therapy
6.3.7. Other

7. Europe
7.1. Europe Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Country, 2016-2028(US$ Bn)
7.1.1. UK
7.1.2. France
7.1.3. Germany
7.1.4. Italy
7.1.5. Russia
7.1.6. Ukraine
7.1.7. Spain
7.1.8. Belgium
7.1.9. Netherland
7.1.10. Austria
7.1.11. Sweden
7.1.12. Poland
7.1.13. Denmark
7.1.14. Switzerland
7.1.15. Rest of Europe
7.2. Europe Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Route of Administration, 2016-2028(US$ Bn)
7.2.1. Overview
7.2.2. Oral
7.2.3. Parenteral
7.2.4. Intravenous
7.2.5. Subcutaneous
7.2.6. Topicals
7.2.7. Others
7.3. Europe Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Molecule Type, 2016-2028(US$ Bn)
7.3.1. Overview
7.3.2. Monoclonal Antibody
7.3.3. Peptides
7.3.4. Polymer
7.3.5. Small molecule
7.3.6. Gene therapy
7.3.7. Other

8. Asia Pacific
8.1. Asia Pacific Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Country, 2016-2028(US$ Bn)
8.1.1. China
8.1.2. Japan
8.1.3. South Korea
8.1.4. India
8.1.5. Australia
8.1.6. New Zealand
8.1.7. Taiwan
8.1.8. Indonesia
8.1.9. Malaysia
8.1.10. Philippine
8.1.11. Rest of Asia Pacific
8.2. Asia Pacific Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Route of Administration, 2016-2028(US$ Bn)
8.2.1. Overview
8.2.2. Oral
8.2.3. Parenteral
8.2.4. Intravenous
8.2.5. Subcutaneous
8.2.6. Topicals
8.2.7. Others
8.3. Asia Pacific Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Molecule Type, 2016-2028(US$ Bn)
8.3.1. Overview
8.3.2. Monoclonal Antibody
8.3.3. Peptides
8.3.4. Polymer
8.3.5. Small molecule
8.3.6. Gene therapy
8.3.7. Other

9. Latin America
9.1. Latin America Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Country, 2016-2028(US$ Bn)
9.1.1. Brazil
9.1.2. Argentina
9.1.3. Peru
9.1.4. Chile
9.1.5. Colombia
9.1.6. Rest of Latin America
9.2. Latin America Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Route of Administration, 2016-2028(US$ Bn)
9.2.1. Overview
9.2.2. Oral
9.2.3. Parenteral
9.2.4. Intravenous
9.2.5. Subcutaneous
9.2.6. Topicals
9.2.7. Others
9.3. Latin America Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Molecule Type, 2016-2028(US$ Bn)
9.3.1. Overview
9.3.2. Monoclonal Antibody
9.3.3. Peptides
9.3.4. Polymer
9.3.5. Small molecule
9.3.6. Gene therapy
9.3.7. Other

10. Middle East
10.1. Middle East Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Country, 2016-2028(US$ Bn)
10.1.1. UAE
10.1.2. KSA
10.1.3. Israel
10.1.4. Turkey
10.1.5. Iran
10.1.6. Rest of Middle East
10.2. Middle East Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Route of Administration, 2016-2028(US$ Bn)
10.2.1. Overview
10.2.2. Oral
10.2.3. Parenteral
10.2.4. Intravenous
10.2.5. Subcutaneous
10.2.6. Topicals
10.2.7. Others
10.3. Middle East Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Molecule Type, 2016-2028(US$ Bn)
10.3.1. Overview
10.3.2. Monoclonal Antibody
10.3.3. Peptides
10.3.4. Polymer
10.3.5. Small molecule
10.3.6. Gene therapy
10.3.7. Other

11. Africa
11.1. Africa Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Country, 2016-2028(US$ Bn)
11.1.1. South Africa
11.1.2. Egypt
11.1.3. Nigeria
11.1.4. Rest of Africa
11.2. Africa Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Route of Administration, 2016-2028(US$ Bn)
11.2.1. Overview
11.2.2. Oral
11.2.3. Parenteral
11.2.4. Intravenous
11.2.5. Subcutaneous
11.2.6. Topicals
11.2.7. Others
11.3. Africa Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Molecule Type, 2016-2028(US$ Bn)
11.3.1. Overview
11.3.2. Monoclonal Antibody
11.3.3. Peptides
11.3.4. Polymer
11.3.5. Small molecule
11.3.6. Gene therapy
11.3.7. Other

12. Global
12.1. Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Route of Administration, 2016-2028(US$ Bn)
12.1.1. Overview
12.1.2. Oral
12.1.3. Parenteral
12.1.4. Intravenous
12.1.5. Subcutaneous
12.1.6. Topicals
12.1.7. Others
12.2. Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Molecule Type, 2016-2028(US$ Bn)
12.2.1. Overview
12.2.2. Monoclonal Antibody
12.2.3. Peptides
12.2.4. Polymer
12.2.5. Small molecule
12.2.6. Gene therapy
12.2.7. Other

13. Company Profiles
13.1. NEC Corporation
13.2. BrightPath therapeutics
13.3. CUREVAC N.V.
13.4. Geneos Therapeutics
13.5. Vaccibody
13.6. Transgene
13.7. Neon Therapeutic
13.8. Genocea Biosciences
13.9. Moderna
13.10. Advaxis
13.11. AstraZeneca
13.12. Gritstone Oncology, Inc.
13.13. Incyte Corporation
13.14. Hangzhou Neoantigen Therapeutics
13.15. Frame Pharmaceuticals
13.16. Others

List of Figures
FIG. 1 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market Segmentation
FIG. 4 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Route of Administration, 2019 (US$ Bn)
FIG. 5 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Molecule Type, 2021 (US$ Bn)
FIG. 6 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Geography, 2021 (US$ Bn)
FIG. 7 Attractive Investment Proposition, by Geography, 2021
FIG. 8 Global Market Positioning of Key Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market Manufacturers, 2019
FIG. 9 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market Value Contribution, By Route of Administration, 2021 & 2028 (Value %)
FIG. 10 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Parenteral, Value, 2016-2028 (US$ Bn)
FIG. 11 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Intravenous, Value, 2016-2028 (US$ Bn)
FIG. 12 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Subcutaneous, Value, 2016-2028 (US$ Bn)
FIG. 13 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Topicals, Value, 2016-2028 (US$ Bn)
FIG. 14 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Others, Value, 2016-2028 (US$ Bn)
FIG. 15 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market Value Contribution, By Molecule Type, 2021 & 2028 (Value %)
FIG. 16 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Monoclonal Antibody, Value, 2016-2028 (US$ Bn)
FIG. 17 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Peptides, Value, 2016-2028 (US$ Bn)
FIG. 18 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Polymer, Value, 2016-2028 (US$ Bn)
FIG. 19 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Small molecule, Value, 2016-2028 (US$ Bn)
FIG. 20 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Gene therapy, Value, 2016-2028 (US$ Bn)
FIG. 21 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Others, Value, 2016-2028 (US$ Bn)
FIG. 22 U.S. Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 23 Rest of North America Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 24 U.K. Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 25 Germany Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 26 France Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 27 Italy Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 28 Spain Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 29 Russia Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 30 BENELUX Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 31 Poland Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 32 Austria Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 33 Rest of Europe Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 34 Japan Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 35 China Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 36 India Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 37 South Korea Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 38 Australia Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 39 Southeast Asia Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 40 Rest of Asia Pacific Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 41 Middle East & Africa Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 42 South Africa Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 43 Nigeria Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 44 Egypt Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 45 GCC Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 46 Israel Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 47 Latin America Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 48 Mechanicalzil Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 49 Argentina Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 50 Colombia Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 51 Peru Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)
FIG. 52 Chile Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, 2016-2028 (US$ Bn)

List of Tables
TABLE 1 Market Snapshot: Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market
TABLE 2 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Route of Administration, 2016-2028 (US$ Bn)
TABLE 3 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Molecule Type, 2016-2028 (US$ Bn)
TABLE 4 Global Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Geography, 2016-2028 (US$ Bn)
TABLE 5 North America Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Route of Administration, 2016-2028 (US$ Bn)
TABLE 6 North America Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Molecule Type, 2016-2028 (US$ Bn)
TABLE 7 North America Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Country, 2016-2028 (US$ Bn)
TABLE 8 Europe Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Route of Administration, 2016-2028 (US$ Bn)
TABLE 9 Europe Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Molecule Type, 2016-2028 (US$ Bn)
TABLE 10 Europe Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 11 Asia Pacific Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Route of Administration, 2016-2028 (US$ Bn)
TABLE 12 Asia Pacific Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Molecule Type, 2016-2028 (US$ Bn)
TABLE 13 Asia Pacific Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 14 Latin America Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Route of Administration, 2016-2028 (US$ Bn)
TABLE 15 Latin America Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Molecule Type, 2016-2028 (US$ Bn)
TABLE 16 Latin America Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 17 Middle East Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Route of Administration, 2016-2028 (US$ Bn)
TABLE 18 Middle East Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Molecule Type, 2016-2028 (US$ Bn)
TABLE 19 Middle East Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Country/Region, 2016-2028 (US$ Bn)
TABLE 20 Africa Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Route of Administration, 2016-2028 (US$ Bn)
TABLE 21 Africa Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Molecule Type, 2016-2028 (US$ Bn)
TABLE 22 Africa Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market, by Country/Region, 2016-2028 (US$ Bn)

Frequently asked questions

How does COVID-19 Impact the global Neoantigen-Based Personalized Cancer Therapeutic Vaccines market?

The global Neoantigen-Based Personalized Cancer Therapeutic Vaccines market is expected to be impacted significantly by COVID-19.

Which is the leading market for Neoantigen-Based Personalized Cancer Therapeutic Vaccines?

North America accounted for the highest share in the global Neoantigen-Based Personalized Cancer Therapeutic Vaccines market in terms of value.

What are the key drivers for the growth of the Neoantigen-Based Personalized Cancer Therapeutic Vaccines market?

The market for Neoantigen-Based Personalized Cancer Therapeutic Vaccines has grown primarily as a result of major market drivers such as rising cancer prevalence, increased adoption of personalised medicine to tailor patient treatment on an individual level, and significant external funding for R&D.

Which is the major route of administration segment in Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market by drugs by route of administration?

Subcutaneous segment had a major share in 2021 with more than 40% of the market revenue share.

Which is the major molecule Route of Administration segment in Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market by molecule Route of Administration?

Gene Therapy segment had a major share in 2021 with more than 30% of the market revenue share.

Orthopedic Splints and Casts Market

Published:
Report ID: 18021

Vietnam Medical Laser Market

Published:
Report ID: 38377

Atrial Fibrillation Devices Market

Published:
Report ID: 2420

Atherectomy Devices Market

Published:
Report ID: 2391

US Pharmacy Automation Market

Published:
Report ID: 38274

Veterinary Hematology Analyzers Market

Published:
Report ID: 11808

Franz Cell and Vapometer Market

Published:
Report ID: 37491

Europe Elderly Care Services Market

Published:
Report ID: 37291

Blood and Fluid Warming Systems Market

Published:
Report ID: 2312

India Wound Care Market

Published:
Report ID: 37156

Negative Pressure Wound Therapy Market

Published:
Report ID: 14408

Smart Insulin Pens Market

Published:
Report ID: 37000

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN